USD 31.97
(-5.69%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 219.1 Million USD | 8594.76% |
2022 | 2.52 Million USD | -57.28% |
2021 | 5.89 Million USD | 2757.21% |
2020 | -222 Thousand USD | -70.77% |
2019 | -130 Thousand USD | -303.13% |
2018 | 64 Thousand USD | -8.61% |
2017 | 70.02 Thousand USD | -21.69% |
2016 | 89.42 Thousand USD | -41.32% |
2015 | 152.38 Thousand USD | 0.0% |
2014 | 152.38 Thousand USD | 0.0% |
2013 | 152.38 Thousand USD | 699.98% |
2012 | 19.04 Thousand USD | 0.0% |
2011 | - USD | 0.0% |
2010 | - USD | 0.0% |
2009 | - USD | 0.0% |
2008 | - USD | 0.0% |
2007 | - USD | 0.0% |
2006 | - USD | 0.0% |
2005 | - USD | 0.0% |
2004 | - USD | 0.0% |
2003 | - USD | -100.0% |
2002 | 500 Thousand USD | -20.55% |
2001 | 629.35 Thousand USD | -51.57% |
2000 | 1.29 Million USD | 224.9% |
1999 | 400 Thousand USD | -87.5% |
1998 | 3.2 Million USD | 1500.0% |
1997 | 200 Thousand USD | 100.0% |
1996 | 100 Thousand USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 57.95 Million USD | 60.86% |
2024 Q2 | 65.09 Million USD | 12.32% |
2024 Q3 | 74.53 Million USD | 14.52% |
2023 Q2 | 14.16 Million USD | 103.9% |
2023 Q4 | 36.02 Million USD | -77.8% |
2023 Q1 | 6.94 Million USD | 8920.78% |
2023 FY | 219.1 Million USD | 8594.76% |
2023 Q3 | 162.3 Million USD | 1045.99% |
2022 Q3 | 92 Thousand USD | -83.89% |
2022 Q4 | 77 Thousand USD | -16.3% |
2022 Q2 | 571 Thousand USD | -67.9% |
2022 FY | 2.52 Million USD | -57.28% |
2022 Q1 | 1.77 Million USD | -15.73% |
2021 Q1 | 654 Thousand USD | 100.24% |
2021 FY | 5.89 Million USD | 2757.21% |
2021 Q2 | 1.39 Million USD | 113.61% |
2021 Q3 | 1.73 Million USD | 24.41% |
2021 Q4 | 2.11 Million USD | 21.46% |
2020 Q4 | -273.55 Million USD | -719984.21% |
2020 Q3 | 38 Thousand USD | 0.0% |
2020 Q1 | 38 Thousand USD | 100.02% |
2020 FY | -222 Thousand USD | -70.77% |
2020 Q2 | 38 Thousand USD | 0.0% |
2019 FY | -130 Thousand USD | -303.13% |
2019 Q4 | -169.01 Million USD | -444881.58% |
2019 Q1 | 38 Thousand USD | 0.0% |
2019 Q2 | 38 Thousand USD | 0.0% |
2019 Q3 | 38 Thousand USD | 0.0% |
2018 Q3 | 38 Thousand USD | 0.0% |
2018 Q4 | 38 Thousand USD | 0.0% |
2018 FY | 64 Thousand USD | -8.61% |
2018 Q1 | 38 Thousand USD | -0.25% |
2018 Q2 | 38 Thousand USD | 0.0% |
2017 Q3 | 38.09 Thousand USD | 0.0% |
2017 FY | 70.02 Thousand USD | -21.69% |
2017 Q4 | 38.09 Thousand USD | -0.0% |
2017 Q1 | 38.09 Thousand USD | 100.0% |
2017 Q2 | 38.09 Thousand USD | 0.0% |
2016 FY | 89.42 Thousand USD | -41.32% |
2016 Q1 | 38.09 Thousand USD | 0.0% |
2016 Q2 | 38.09 Thousand USD | 0.0% |
2016 Q3 | 38.09 Thousand USD | 0.0% |
2016 Q4 | -78.96 Billion USD | -207289815.21% |
2015 Q4 | 38.09 Thousand USD | -0.0% |
2015 Q1 | 38.09 Thousand USD | 100.07% |
2015 Q2 | 38.09 Thousand USD | 0.0% |
2015 Q3 | 38.09 Thousand USD | 0.0% |
2015 FY | 152.38 Thousand USD | 0.0% |
2014 Q4 | -55.68 Million USD | -146264.94% |
2014 FY | 152.38 Thousand USD | 0.0% |
2014 Q3 | 38.09 Thousand USD | 0.0% |
2014 Q2 | 38.09 Thousand USD | 0.0% |
2014 Q1 | 38.09 Thousand USD | 100.17% |
2013 Q2 | 38.09 Thousand USD | 0.0% |
2013 Q1 | 38.09 Thousand USD | 100.14% |
2013 FY | 152.38 Thousand USD | 699.98% |
2013 Q4 | -22.92 Million USD | -60284.52% |
2013 Q3 | 38.09 Thousand USD | 0.0% |
2012 Q3 | - USD | 0.0% |
2012 Q4 | -26.87 Million USD | 0.0% |
2012 FY | 19.04 Thousand USD | 0.0% |
2012 Q1 | - USD | 0.0% |
2012 Q2 | - USD | 0.0% |
2011 Q2 | - USD | 0.0% |
2011 Q3 | - USD | 0.0% |
2011 FY | - USD | 0.0% |
2011 Q4 | - USD | 0.0% |
2011 Q1 | - USD | 0.0% |
2010 Q1 | - USD | 0.0% |
2010 Q2 | - USD | 0.0% |
2010 Q3 | - USD | 0.0% |
2010 FY | - USD | 0.0% |
2010 Q4 | - USD | 0.0% |
2009 Q2 | - USD | 0.0% |
2009 Q3 | - USD | 0.0% |
2009 FY | - USD | 0.0% |
2009 Q4 | - USD | 0.0% |
2009 Q1 | - USD | 0.0% |
2008 Q3 | - USD | 0.0% |
2008 Q4 | - USD | 0.0% |
2008 FY | - USD | 0.0% |
2008 Q1 | - USD | 0.0% |
2008 Q2 | - USD | 0.0% |
2007 Q1 | - USD | 100.0% |
2007 Q4 | - USD | 0.0% |
2007 Q3 | - USD | 0.0% |
2007 Q2 | - USD | 0.0% |
2007 FY | - USD | 0.0% |
2006 Q1 | - USD | 0.0% |
2006 Q2 | - USD | 0.0% |
2006 Q4 | -85.06 Thousand USD | 0.0% |
2006 Q3 | - USD | 0.0% |
2006 FY | - USD | 0.0% |
2005 Q4 | - USD | 0.0% |
2005 Q2 | - USD | 0.0% |
2005 FY | - USD | 0.0% |
2005 Q1 | - USD | 0.0% |
2005 Q3 | - USD | 0.0% |
2004 Q3 | - USD | 0.0% |
2004 Q1 | - USD | 0.0% |
2004 Q4 | - USD | 0.0% |
2004 FY | - USD | 0.0% |
2004 Q2 | - USD | 0.0% |
2003 FY | - USD | -100.0% |
2003 Q1 | - USD | 0.0% |
2003 Q2 | - USD | 0.0% |
2003 Q3 | - USD | 0.0% |
2003 Q4 | - USD | 0.0% |
2002 Q1 | - USD | 0.0% |
2002 Q3 | - USD | -100.0% |
2002 FY | 500 Thousand USD | -20.55% |
2002 Q4 | - USD | 0.0% |
2002 Q2 | 500 Thousand USD | 0.0% |
2001 Q4 | - USD | 0.0% |
2001 FY | 629.35 Thousand USD | -51.57% |
2001 Q1 | 656.29 Thousand USD | 19.09% |
2001 Q2 | -295.31 Thousand USD | -145.0% |
2001 Q3 | - USD | 100.0% |
2000 Q3 | 233.34 Thousand USD | -23.22% |
2000 Q1 | 211.26 Thousand USD | 5.63% |
2000 FY | 1.29 Million USD | 224.9% |
2000 Q2 | 303.89 Thousand USD | 43.85% |
2000 Q4 | 551.1 Thousand USD | 136.18% |
1999 FY | 400 Thousand USD | -87.5% |
1999 Q4 | 200 Thousand USD | 100.0% |
1999 Q3 | 100 Thousand USD | 0.0% |
1999 Q2 | 100 Thousand USD | 0.0% |
1999 Q1 | 100 Thousand USD | -83.33% |
1998 FY | 3.2 Million USD | 1500.0% |
1998 Q2 | 2.5 Million USD | 2400.0% |
1998 Q3 | 100 Thousand USD | -96.0% |
1998 Q4 | 600 Thousand USD | 500.0% |
1998 Q1 | 100 Thousand USD | 0.0% |
1997 Q3 | 100 Thousand USD | 0.0% |
1997 Q4 | - USD | -100.0% |
1997 FY | 200 Thousand USD | 100.0% |
1997 Q1 | 100 Thousand USD | 0.0% |
1997 Q2 | 100 Thousand USD | 0.0% |
1996 Q3 | 100 Thousand USD | 0.0% |
1996 Q4 | - USD | -100.0% |
1996 FY | 100 Thousand USD | 0.0% |
1996 Q1 | 100 Thousand USD | 0.0% |
1996 Q2 | 100 Thousand USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Thermo Fisher Scientific Inc. | 15.22 Billion USD | 98.561% |
Dynavax Technologies Corporation | 182.11 Million USD | -20.312% |
Illumina, Inc. | 2.74 Billion USD | 92.015% |
IQVIA Holdings Inc. | 5.23 Billion USD | 95.818% |
Biogen Inc. | 7.3 Billion USD | 96.999% |
Iovance Biotherapeutics, Inc. | -9.56 Million USD | 2390.487% |
Mettler-Toledo International Inc. | 2.16 Billion USD | 89.899% |
Sarepta Therapeutics, Inc. | 1.09 Billion USD | 79.953% |
Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 58.165% |
Waters Corporation | 1.76 Billion USD | 87.559% |
Perrigo Company plc | 1.68 Billion USD | 86.961% |
uniQure N.V. | 2.21 Million USD | -9792.009% |
Agios Pharmaceuticals, Inc. | 17.31 Million USD | -1165.131% |
Amicus Therapeutics, Inc. | 362.03 Million USD | 39.478% |
Atara Biotherapeutics, Inc. | -313 Thousand USD | 70102.556% |
bluebird bio, Inc. | -4.03 Million USD | 5536.923% |
Cara Therapeutics, Inc. | 14.79 Million USD | -1381.06% |
Imunon, Inc. | -720 Thousand USD | 30531.455% |
Myriad Genetics, Inc. | 476.4 Million USD | 54.008% |
Neurocrine Biosciences, Inc. | 1.84 Billion USD | 88.14% |
Nektar Therapeutics | 53.47 Million USD | -309.716% |
Editas Medicine, Inc. | -99.52 Million USD | 320.147% |
Verastem, Inc. | -62 Thousand USD | 353500.0% |
Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 99.174% |
Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 802.998% |
Heron Therapeutics, Inc. | 10.04 Million USD | -2081.916% |
Unity Biotechnology, Inc. | -19.69 Million USD | 1212.28% |
BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 88.494% |
Sangamo Therapeutics, Inc. | -45.32 Million USD | 583.415% |
Evolus, Inc. | 140.52 Million USD | -55.92% |
Adicet Bio, Inc. | -6.09 Million USD | 3693.112% |
Aclaris Therapeutics, Inc. | -85.21 Million USD | 357.121% |
Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 98.061% |
Esperion Therapeutics, Inc. | 73.06 Million USD | -199.873% |
FibroGen, Inc. | 128.9 Million USD | -69.978% |
Agilent Technologies, Inc. | 3.46 Billion USD | 93.677% |
OPKO Health, Inc. | 318.12 Million USD | 31.126% |
Homology Medicines, Inc. | -7.22 Million USD | 3130.959% |
Geron Corporation | -123.5 Million USD | 277.411% |
Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 85.565% |
Exelixis, Inc. | 1.75 Billion USD | 87.534% |
Viking Therapeutics, Inc. | -292 Thousand USD | 75136.986% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
Intellia Therapeutics, Inc. | -398.79 Million USD | 154.943% |
Zoetis Inc. | 5.83 Billion USD | 96.244% |
Axsome Therapeutics, Inc. | 244.53 Million USD | 10.398% |
Abeona Therapeutics Inc. | 302 Thousand USD | -72452.318% |
Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 97.454% |
Kala Pharmaceuticals, Inc. | -303 Thousand USD | 72412.871% |
Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 71.856% |
Corcept Therapeutics Incorporated | 475.89 Million USD | 53.959% |
Halozyme Therapeutics, Inc. | 636.89 Million USD | 65.597% |
Blueprint Medicines Corporation | 236.58 Million USD | 7.387% |
Insmed Incorporated | 239.63 Million USD | 8.566% |
Incyte Corporation | 3.44 Billion USD | 93.632% |
Emergent BioSolutions Inc. | 343.9 Million USD | 36.287% |